At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...

Viatris (VTRS) is set to announce Q2 earnings amid EPS and revenue declines. Learn about its recent trials, stock dip, and Wall Street's Hold rating.

BridgeBio Pharma Inc (BBIO) reports a remarkable 100% growth in U.S. net sales and outlines future opportunities amidst ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

Snap SNAP reported second-quarter revenue of $1.3 billion, up 9% year over year, largely due to strength in European markets.

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...